During the recent session, Adma Biologics Inc (NASDAQ:ADMA)’s traded shares were 0.43 million, with the beta value of the company hitting 0.54. At the last check today, the stock’s price was $20.04, reflecting an intraday loss of -1.18% or -$0.24. The 52-week high for the ADMA share is $23.64, that puts it down -17.96 from that peak though still a striking 70.61% gain since the share price plummeted to a 52-week low of $5.89. The company’s market capitalization is $4.76B, and the average intraday trading volume over the past 10 days was 3.68 million shares, and the average trade volume was 2.70 million shares over the past three months.
Adma Biologics Inc (ADMA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ADMA has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.14.
Adma Biologics Inc (NASDAQ:ADMA) trade information
Adma Biologics Inc (ADMA) registered a -1.18% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.18% in intraday trading to $20.04, hitting a weekly high. The stock’s 5-day price performance is 1.21%, and it has moved by 29.79% in 30 days. Based on these gigs, the overall price performance for the year is 208.31%. The short interest in Adma Biologics Inc (NASDAQ:ADMA) is 15.07 million shares and it means that shorts have 5.3 day(s) to cover.
The consensus price target of analysts on Wall Street is $18, which implies a decrease of -11.33% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $18 and $18 respectively. As a result, ADMA is trading at a premium of 10.18% off the target high and 10.18% off the low.
Adma Biologics Inc (ADMA) estimates and forecasts
In the rating firms’ projections, revenue will increase 16.13% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 116.4M as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 121.3M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 81.88M and 107.19M respectively. In this case, analysts expect current quarter sales to grow by 42.17% and then jump by 13.16% in the coming quarter.
ADMA Dividends
Adma Biologics Inc is due to release its next quarterly earnings on 2025-Mar-02. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Adma Biologics Inc (NASDAQ:ADMA)’s Major holders
Adma Biologics Inc insiders own 2.60% of total outstanding shares while institutional holders control 88.43%, with the float percentage being 90.79%. BLACKROCK INC. is the largest shareholder of the company, while 438.0 institutions own stock in it. As of 2024-06-30, the company held over 18.64 million shares (or 8.0221% of all shares), a total value of $208.45 million in shares.
The next largest institutional holding, with 14.52 million shares, is of VANGUARD GROUP INC’s that is approximately 6.3426% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $162.3 million.
Also, the Mutual Funds coming in first place with the largest holdings of Adma Biologics Inc (ADMA) shares are iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund. Data provided on Feb 28, 2025 indicates that iShares Trust-iShares Core S&P Small-Cap ETF owns about 15.07 shares. This amounts to just over 6.34 percent of the company’s overall shares, with a $297.57 million market value. The same data shows that the other fund manager holds slightly less at 7.0, or about 2.95% of the stock, which is worth about $138.28 million.
